Review
Nature Reviews Immunology 6, 383-393 (May 2006) | doi:10.1038/nri1842
Focus on: Translational immunology
Adoptive immunotherapy for cancer: building on success
Luca Gattinoni1,2, Daniel J. Powell, Jr.1,2, Steven A. Rosenberg2 & Nicholas P. Restifo2 About the authors
Abstract
Adoptive cell transfer after host preconditioning by lymphodepletion represents an important advance in cancer immunotherapy. Here, we describe how a lymphopaenic environment enables tumour-reactive T cells to destroy large burdens of metastatic tumour and how the state of differentiation of the adoptively transferred T cells can affect the outcome of treatment. We also discuss how the translation of these new findings might further improve the efficacy of adoptive cell transfer through the use of vaccines, haematopoietic-stem-cell transplantation, modified preconditioning regimens, and alternative methods for the generation and selection of the T cells to be transferred.
- View At a Glance
Author affiliations
- These authors contributed equally to this work.
- National Cancer Institute, National Institutes of Health, Mark O. Hatfield Clinical Research Center, Room 3-5762, 10 Center Drive, Bethesda, Maryland 20892-1201, USA.
Correspondence to: Luca Gattinoni1,2 Email: gattinol@mail.nih.gov
Correspondence to: Nicholas P. Restifo2 Email: restifo@nih.gov
Published online 18 April 2006
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Mutant deoxynucleotide carrier is associated with congenital microcephalyNature Genetics Letter (01 Sep 2002)
See all 4 matches for Research
